{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:44:21Z","timestamp":1790009061798,"version":"4.0.1"},"reference-count":74,"publisher":"Informa UK Limited","issue":"18","funder":[{"DOI":"10.13039\/100006108","name":"NIH\/National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","award":["#UL1TR00457"],"award-info":[{"award-number":["#UL1TR00457"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2016,9,30]]},"DOI":"10.2217\/fon-2016-0003","type":"journal-article","created":{"date-parts":[[2016,6,21]],"date-time":"2016-06-21T08:09:46Z","timestamp":1466496586000},"page":"2077-2094","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Idelalisib for the Treatment of Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma"],"prefix":"10.1080","volume":"12","author":[{"given":"Jacqueline C","family":"Barrientos","sequence":"first","affiliation":[{"name":"CLL Research & Treatment Program, Division of Hematology\/Oncology, Department of Medicine, Hofstra Northwell School of Medicine, Hofstra University, 410 Lakeville Road, Suite 212, Lake Success, NY11042, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,6,21]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23979"},{"key":"e_1_3_3_4_1","unstructured":"SEER Stat Fact Sheets: Leukemia. http:\/\/seer.cancer.gov\/statfacts\/html\/leuks.html."},{"key":"e_1_3_3_5_1","unstructured":"American Cancer Society\n. Cancer Facts & Figures 2015. www.cancer.org\/acs\/groups\/content\/@editorial\/documents\/document\/acspc-044552.pdf."},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-207126"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.10.861"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.450"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701724785"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.10.127"},{"key":"e_1_3_3_12_1","unstructured":"SEER Stat Fact Sheets: Non-Hodgkin Lymphoma. http:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html."},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107326"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.4236\/jct.2013.48156"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802688517"},{"key":"e_1_3_3_16_1","unstructured":"National Comprehensive Cancer Network\n. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin\u2019s Lymphomas (version 1.2015). www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1061193"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0165-x"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481502204s04"},{"key":"e_1_3_3_20_1","volume-title":"WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008","unstructured":"Swerdlow SH , CampoE, HarrisNLet al. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues . IARC Press, Lyon, France (2008)."},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.4508"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28318"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.19.19"},{"key":"e_1_3_3_25_1","unstructured":"IMBRUVICA \u00ae (ibrutinib capsules)\n. Full Prescribing Information. Janssen Biotech Inc. Horsham PA USA (2016)."},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_3_3_27_1","unstructured":"VENCLEXTA\u2122 (venetoclax tablets)\n. Full Prescribing Information. AbbVie Inc. North Chicago IL USA (2016)."},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-630947"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275305"},{"key":"e_1_3_3_31_1","unstructured":"ZYDELIG \u00ae (idelalisib tablets)\n. Full Prescribing Information. Gilead Sciences Inc. Foster City CA USA (2014)."},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2882"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.08.041"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.9.4330"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.31.19236"},{"key":"e_1_3_3_36_1","first-page":"931858","article-title":"Idelalisib for the treatment of chronic lymphocytic leukemia","volume":"2014","author":"Khan M","year":"2014","unstructured":"Khan M , SaifA, SandlerS, MirrakhimovAE. Idelalisib for the treatment of chronic lymphocytic leukemia. ISRN Oncol.2014, 931858 (2014).","journal-title":"ISRN Oncol."},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.24.8580-8591.2002"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1073560"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020805"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271171"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352492"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083830"},{"key":"e_1_3_3_43_1","volume-title":"American Society of Hematology Annual Meeting","author":"Webb H","year":"2010","unstructured":"Webb H , ChenH, YuAet al. Clinical pharmacokinetics of CAL-101, a p110\u03b4 isoform-selective PI3K inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies [Poster I-754]. Presented at: American Society of Hematology Annual Meeting. Orlando, FL, USA, 4\u20137 December 2010."},{"key":"e_1_3_3_44_1","volume-title":"55th American Society of Hematology Annual Meeting and Exposition","author":"Jin F","year":"2013","unstructured":"Jin F , RobesonM, ZhouH, KwanE, RamanathanS. Pharmacokinetics, metabolism and excretion of idelalisib. Presented at: 55th American Society of Hematology Annual Meeting and Exposition. New Orleans, LA, USA, 7\u201310 December 2013."},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2898-1"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.504"},{"key":"e_1_3_3_47_1","unstructured":"European Medicines Agency\n. Idelalisib. Summary of Product Characteristics. www.medicines.org.uk\/emc\/medicine\/29202."},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3343.3343"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4180.4180"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.1986.1986"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.LBA-5.LBA-5"},{"key":"e_1_3_3_54_1","volume-title":"XVI International Workshop on Chronic Lymphocytic Leukemia","author":"Zelenetz A","year":"2015","unstructured":"Zelenetz A , LamannaN, KippsTet al. A Phase 2 study of idelalisib monotherapy in previously untreated patients \u226565 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Presented at: XVI International Workshop on Chronic Lymphocytic Leukemia. Sydney, Australia, 6\u20139 September 2015."},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.330.330"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.497.497"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1022770"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.036152"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.1990.1990"},{"key":"e_1_3_3_60_1","volume-title":"ASCO Annual Meeting","author":"Barrientos J","year":"2015","unstructured":"Barrientos J , GhiaP, PagelJet al. Outcomes of anticoagulant or antiplatelet use in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma in idelalisib trials. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 29 May\u20132 June 2015."},{"key":"e_1_3_3_61_1","unstructured":"FDA alerts healthcare professionals about clinical trials with Zydelig (idelalisib) in combination with other cancer medicines. www.fda.gov\/Drugs\/DrugSafety\/ucm490618.htm."},{"key":"e_1_3_3_62_1","unstructured":"Direct Healthcare Professional Communication: restrictions on the use of Zydelig \u00ae (idelalisib) for the treatment of chronic lymphocytic leukaemia (CLL) and relapsed follicular lymphoma (FL) following new clinical trial results. www.hpra.ie\/docs\/default-source\/default-document-library\/important-safety-information---zydelig-(idelalisib).pdf?sfvrsn=0."},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-603670"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.719.719"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.4155.4155"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-586826"},{"issue":"1","key":"e_1_3_3_69_1","first-page":"154","article-title":"Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-delta, gamma inhibitor, in patients with treatment-na\u00efve CLL","volume":"100","author":"O\u2019Brien S","year":"2015","unstructured":"O\u2019Brien S , FaiaK, WhiteKet al. Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-delta, gamma inhibitor, in patients with treatment-na\u00efve CLL. Haematologica100(Suppl. 1), 154\u2013155 (2015).","journal-title":"Haematologica"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3334.3334"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3335.3335"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.4154.4154"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.LBA-6.LBA-6"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633156"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3091.3091"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2016-0003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:29Z","timestamp":1719125009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2016-0003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,21]]},"references-count":74,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2016,9,30]]}},"alternative-id":["10.2217\/fon-2016-0003"],"URL":"https:\/\/doi.org\/10.2217\/fon-2016-0003","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}